This preview shows page 1. Sign up to view the full content.
Unformatted text preview: .35 or This article ranby ejection fraction of cell- less were endomly assigned
trial. The risks of hospitalization for heart failure and
type–specific defined by as seen in
rolled from the action March 1989. A single published on July
progression of heart failure asmarkers anddeath from recordings of June 1986 to potentials in prerandomization run-in 21, 2010, at NEJM.org.
phase consisted prolonged in active-drug phase
cells. composite end point of potential was markedly of a single-blind “ventricular” (2 to 7 days)
pump failure and the The duration of the action death
or hospitalization for heart failure were compared in with long-QT a placebo run-in phase (14 to 17 days). Patients with
and “atrial” cells derived from patients
syndrome type 1, as compared N Engl J© 20102010.
Massachusetts Medical Society.
worsening heart failure during this phase were excluded from the
patients with these findings on control subjects. Further characterization of the role of the R190Q–
with cells from
trial. Treatment was initiated predominantly in the outpatient setand patients without these findings.
ting (in syndrome cases). revealed a domKCNQ1 mutation in the pathogenesis of long-QT99 percent of type 1The participants were followed for an
Results In multivariate analyses that were adjustaverage
inant of the severity of heart failure,
negative trafficking defect associated with(±SD) to 32±15reduction in IKs protocol was approved
a 70 of 80% months. The study cured for other markers
by the appropriate review boards of the participating centers, and
rent and pressure was activation
deactivation consent was Moreover, we
elevated jugular venous altered channel associated andwritten informed properties.obtained from the patients.
showed hospitalization for heart failwith an increased risk ofthat myocytes derived from patients with long-QT syndrome type 1 had an
Data Collection and Definitions
ure (relative risk,increasedpercent confidence interval,
1.32; 95 susceptibility to catecholamine-induced tachyarrhythm...
View Full Document
- Fall '14